About

Biog:

I received my PhD from the University of Wales Aberystwyth (UK) in 2008 and immediately joined the JCU Vascular Biology Unit as a junior post-doctoral scientist. I was appointed to the position of Senior Scientist (Academic B) within the Vascular Biology Unit in 2011. I secured a competitive Advance Queensland Fellowship in 2017, coinciding with my promotion to Senior Research Fellow (Academic C). I was the interim honours program coordinator for the College of Medicine and Dentistry (2018) and was invited to my current position of Associate Dean Research for the College of Medicine and Dentistry in 2019. I provide strategic leadership at the College, Division and University level, whilst maintaining a highly active research portfolio. 

Research: 

My research focuses on peripheral artery disease (PAD), a common condition affecting up to one quarter of older adults. PAD causes blockage, or weakening of the arteries outside the heart and can only be treated through surgery which is expensive and has limited durability. Patients with PAD are also at significantly increased risk of suffering major cardiovascular events such as heart attack and stroke. My research is conducted in collaboration with clinicians and scientists and utilises clinical, laboratory and data-driven approaches to:

  • Identify novel blood-based markers to diagnose, or predict risk of suffering PAD-associated events (e.g. heart attack, or requirement for surgery);
  • Test novel medications for PAD - most recently through the delivery of randomised controlled trials as lead analyst;
  • Identify barriers to care in underserved populations, particularly for those in regional areas.

In 2017 I secured a competitive Advance Queensland Fellowship enabling the establishment of an ongoing prospective cohort of participants presenting to hospital with suspected stroke. Ongoing research in this area utilises cutting edge sequencing techniques and interrogation of existing datasets to identify markers which may ultimately form the basis of rapid diagnostic tests.

Student Supervision:

Student supervision is one of the aspects of my job that I most enjoy and I have been privileged to work with some talented students since joining JCU. To date, I have (co)-supervised 4 PhD students, one MSc student and 8 honours students to successful completion. 

I currently co-supervise 4 PhD students, and am always happy to hear from any research curious candidates at any level. Interested students are encouraged to contact me with a copy of their CV and an outline of their research interests.

 

Other Academic Activities:

Editorial board memberships:

    • BMC Cardiovascular Disorders (2018-present);
    • International Journal of Molecular sciences (2013-2020; including collation of a special edition titled 'Advances in Peripheral Artery Disease')

Grant review for a range of bodies including the NHMRC, Diabetes Australia, Dunhill Trust and Imperial College London

Teaching
  • HS7405: Research Methodologies for Health Professionals (Level 7; TSV)
  • MD1010: Introduction to Integrated Medical Studies Part 1 of 2 (Level 1; TSV)
  • MD3011: Introduction to Clinical Healthcare Part 1 of 2 (Level 3; TSV)
  • MD3012: Introduction to Clinical Healthcare Part 2 of 2 (Level 3; TSV)
Interests
Professional
  • Vascular Disease
Research
  • Abdominal Aortic Aneurysm
  • Peripheral Artery Disease
  • Stroke
  • Meta-analysis
  • Biostatistics
  • Clinical trials
  • Biomarker Discovery
Teaching
  • Research mentoring
Experience
  • 2019 to present - Associate Dean, Research, JCU College of Medicine and Dentistry (Australia)
  • 2017 to present - Senior Research Fellow (ACAD C), JCU College of Medicine and Dentistry, (Australia)
  • 2018 - Honours program coordinator, JCU College of Medicine and Dentistry (Australia)
  • 2011 to 2016 - Senior Scientist, JCU College of Medicine and Dentistry, James Cook University (Australia)
  • 2008 to 2011 - Post-doctoral Scientist, JCU College of Medicine and Dentistry, James Cook University (Australia)
  • 2008 - Research Assistant, The University of Wales Aberystwyth (UK)
  • 2004 to 2008 - PhD Student, The University of Wales Aberystwyth (UK)
Research Disciplines
Socio-Economic Objectives
Honours
Awards
  • 2020 - Philanthropic research donation from the Donald and Joan Wilson Foundation ($40,000)
  • 2016 to 2017 - The Townsville Hospital SERTA grant. 'Physical activity, sedentary behaviour, physical performance and frailty in patients with peripheral artery disease.' $40,000. Golledge J, Moxon JV, Leicht A, Mudge A, Biros E, Best S, Yip L.
  • 2016 to 2017 - The Townsville Hospital SERTA grant . 'Developing a case-control cohort to examine the treatment targets for peripheral vascular diseases.' $169,306. Biros E, Field M, Golledge J, Krishna S, Leicht A, Moxon J, Woodward L.
  • 2016 to 2017 - The Townsville Hospital SERTA grant . 'The role of circulating blood markers to diagnose endoleak after endovascular repair of abdominal aortic aneurysm (EVAR)'. $14,000. Velu R, Ng E, Golledge J, Moxon JV, Biros E, Lazzaroni S, Fitridge R, Boult M
  • 2016 - The Townsville Hospital SERTA grant 'Identifying lipid markers to predict outcomes for patients with peripheral artery disease' ($10,000)
  • 2016 - Research Infrastructure Building Grant 'Part time clinical trials co-ordinator' ($39,110)
  • 2016 - Travel grant to attend and present at the 2016 meeting of the European Atherosclerosis Society (Innsbruck, Austria; total value: $1,250).
  • 2016 - Travel grant from the International Journal of Molecular Sciences ($650).
  • 2015 to 2016 - Development Grant 'Is inositol a potential therapy for abdominal aortic aneurysm? Building the case to support external funding applications' $80,000, Chief Investigator)
  • 2015 to 2016 - Bridging the Gap grant 'The effect of hookworm proteins on abdominal aortic aneurysm' ($20,000 - Chief Investigator).
  • 2015 - Research Infrastructure Funding ($77,000 - James Cook University RIBG and AITHM, Chief Investigator)
  • 2014 to 2015 - Faculty Administered Internal Grant 'Peripheral arterial disease in Aboriginal and Torres Strait Islanders' ($9,646 - Chief Investigator)
  • 2014 to 2015 - JCU Rising Stars Award - Competitive award given to emerging JCU research leaders ($15,000)
  • 2013 to 2014 - Faculty Administered Internal Grant 'Proteomic and bioinformatic characterisation of the ageing aorta' ($11,500 - Chief Investigator)
  • 2013 - CASS Foundation Early Career Researcher Travel Grant ($3,000)
  • 2012 to 2013 - School of Medicine and Dentistry Internal Administered Grant 'Contribution of ACE2 to human AAA' ($7,500 - Co-investigator)
  • 2012 to 2013 - School of Medicine and Dentistry Internal Administered Grant 'Lipid biomarkers for aneurysm disease' ($7,500 - Chief Investigator)
  • 2011 to 2012 - Competitive Research Incentive Grant - Personal award for highly ranked application to the ARC ($10,000)
  • 2011 to 2012 - Faculty Administered Internal Grant 'Stem cell therapy for aortic aneurysms' ($3,000 - Chief Investigator)
  • 2010 to 2011 - Faculty Administered Internal Grant 'Biomarkers of abdominal aortic aneurysm' ($8,000 - Chief Investigator)
  • 2010 - Research Infrastructure Funding ($12,500 - Chief Investigator)
  • 2009 to 2010 - Faculty Administered Internal Grant 'Aneurysm proteomics: Biomarker discovery' ($7,650 - Chief Investigator)
  • 2009 - Research Infrastructure Funding ($12,800 - Chief Investigator)
Fellowships
  • 2017 to 2020 - Advance Queensland Mid Career Fellowship - 'Clinical and economic evaluation of novel blood tests for stroke'.
Memberships
  • 2021 - The Brain Foundation
  • 2021 - Australian Cerebrovascular Working Group
  • 2016 - The Australian Institute of Tropical Health and Medicine
  • 2015 - The Australian Cardiovascular Alliance
  • 2015 - The European Atherosclerosis Society
  • 2015 - The Australian Atherosclerosis Society
  • 2011 - The Australasian Vascular Biology Society
Publications

These are the most recent publications associated with this author. To see a detailed profile of all publications stored at JCU, visit ResearchOnline@JCU. Hover over Altmetrics badges to see social impact.

Journal Articles
More

ResearchOnline@JCU stores 98+ research outputs authored by Dr Joseph Moxon from 2006 onwards.

Current Funding

Current and recent Research Funding to JCU is shown by funding source and project.

Commonwealth Department of Health - Medical Research Future Fund - Cardiovascular Health Mission

Improving clinical pathways for abdominal aortic aneurysm through incorporating biomarkers

Indicative Funding
$1,000,000 over 3 years
Summary
20 million people worldwide have weakening of their main abdominal artery (abdominal aortic aneurysm; AAA) and are at high risk of both major adverse cardiovascular events (MACE) and AAA related events (AAA repair and rupture-related death). Most AAAs are identified at a small size when their risk of rupture is low. Management of small AAA focuses on repeat aortic imaging every 6 months to identify when the threshold diameter (50mm in women and 55mm in men) is reached for elective surgical AAA repair. Most small AAAs continue to grow in size and eventually undergo repair. No drugs have been shown to limit AAA growth and the clinical pathway focuses on identifying those needing surgery rather than medical management. There are no established means to individualise care. Our interviews with patients and health professionals indicate that the number one deficiency in current AAA management is the lack of individualising medical management to reduce the high incidence of MACE and AAA related events. Our international AAA alliance is uniquely placed due to our resources (biobank-registry) and IP (bioinformatics, clinical, engineering software, genomics, biomarkers, machine learning and pathogenesis) to addresses this unmet clinical need.
Investigators
Jon Golledge, Clare Arnott, Thomas Gasser, Rebecca Evans, Joseph Moxon, Matt Field, Jenna Pinchbeck, Aaron Drovandi, Dylan Morris, Svetha Venkatesh, Truyen Tran, Catherine Rush, Aletta Schutte, Robyn Clay-Williams and Geoffrey Jones (College of Medicine & Dentistry, The George Institute for Global Health, KTH Royal Institute of Technology, College of Public Health, Medical & Vet Sciences, Townsville Hospital and Health Services, Deakin University, The University of New South Wales, Macquarie University and University of Otago)
Keywords
Prevention; Complications; Peripheral artery disease; Risk Factors

Commonwealth Department of Health - Medical Research Future Fund - Dementia, Ageing and Aged Care

METformin for treating peripheral artery disease Related walking Impairment Trial (MERIT)

Indicative Funding
$1,215,182 over 3 years
Summary
Peripheral artery disease (PAD) is a very common chronic cardiovascular disease of ageing affecting approximately 1 million older Australians and causing substantial leg pain on walking (intermittent claudication), marked functional impairment, reduced quality of life (QOL) and very high risk of major adverse cardiovascular and limb events. Vulnerable populations (e.g. regional or remote, lower income and Aboriginal and Torres Strait Islander populations) have much greater PAD-related burden. Our past consultations with patients indicate that improvements in walking is their number one priority. The only widely available PAD treatment in Australia is revascularisation but this does not improve walking distance and has substantial safety concerns. Multiple lines of evidence suggest that metformin safely improves leg blood supply. MERIT is a placebo-controlled randomised trial performed across 7 sites. The importance of the trial has been endorsed by patients, Heart Foundation, Queensland Health and Australian and New Zealand Society for Vascular Surgery and Alliance for Cardiovascular Trials. If positive, MERIT will identify a cheap, safe and widely available drug to improve the function and QOL of millions of older adults worldwide who have PAD.
Investigators
Jon Golledge, Clare Arnott, Edward Strivens, Belinda Parmenter, Clare Heal, Christopher Reid, Aaron Drovandi, Joseph Moxon, Jenna Pinchbeck, Richard Norman, Dylan Morris, Christopher Askew, Sarah Larkins, Rachel Quigley and Yvonne Cadet-James (College of Medicine & Dentistry, The George Institute for Global Health, The University of New South Wales, Curtin University of Technology, Townsville Hospital and Health Services, University of the Sunshine Coast and Indigenous Education & Research Centre)
Keywords
Prevention; Complications; Peripheral artery disease; Risk Factors

Commonwealth Department of Health - Clinician Researchers Initiative

The TEle-Artery triaL (TEAL)

Indicative Funding
$2,862,084 over 3 years
Summary
Approximately 1 million Australians have blockage of their lower limb arteries which causes leg pain and walking impairment that reduces quality of life and increases the risk of amputation and death. Based on a systematic review of past evidence, in collaboration with patients and other key stakeholders we have designed a remotely-supervised exercise program to improve function and quality of life of people with leg artery blockage. This controlled, randomised clinical trial will examine the efficacy of Tele-artery in improving walking ability over 6 months. Positive findings from this trial will be followed by wide dissemination of the program.
Investigators
Jon Golledge, Joseph Moxon, Jenna Pinchbeck, Aaron Drovandi, Rhondda Jones, Juanita Muller, Dylan Morris, Frank Quigley, Bernard Bourke, Ramesh Velu, Erik Lai and Murray Ogg (College of Medicine & Dentistry, Research Division, Queensland Health, Mater Hospital and Central Coast Vascular)
Keywords
Prevention; Complications; Peripheral artery disease; Risk Factors

Tropical Australian Academic Health Centre Limited - Research Seed Grants

Metformin for treating peripheral artery disease-related walking impairment (MERIT)

Indicative Funding
$50,000 over 2 years
Summary
Blockage of the leg arteries (peripheral artery disease; PAD) leads to severe pain, walking impairment and a substantial risk of leg amputation and death. Over 20,000 North Queenslanders have PAD which is overrepresented in regional, remote and rural populations. There are currently no effective PAD medications. Multiple lines of evidence suggest that metformin, a cheap and safe medication, promotes formation of new vessels, improves microcirculation and muscle function and limits PAD-related pain. This placebo-controlled, randomised clinical trial, run by a North Queensland vascular research collaboration, will examine the efficacy of metformin in improving walking ability of PAD patients.
Investigators
Jon Golledge, Alkira Venn and Joseph Moxon (College of Medicine & Dentistry)
Keywords
Prevention; Complications; Preipheral artery disease; Risk Factors

National Health & Medical Research Council - Clinical Trials and Cohort Studies

The Metformin Aneurisym Trial (MAT)

Indicative Funding
$4,997,653 over 5 years
Summary
20 million people worldwide and 100,000 Australians have an abdominal aortic aneurysm (AAA). The main complication of AAA, aortic rupture, leads to 200,000 deaths/year worldwide. AAA prevalence and mortality rates in Australasia are 4-fold higher than the world average, so research to improve management is a key priorty. Most AAAs are detected when theya re small, when an effective treatment would prevent the need for surgery. There is currently no effective drug therapy for AA, and 70% of small AAAs grow to a size requiring surgical repair which carries inherent risks of death and major complications. A large amount of observational data from patients and laboratory models suggest that metformin may be an effective drug therapy for AAA. The metformin aneurysm trial (MAT) will be a large-scale, multi-centre randomised trail done as a collaboration between investigators in Australia, New Zealand, Swden and the United Kingdom across 55 sites over a 5 year trial period. Patients with AAA measuring between 39 and 49mmm in diameter will be enrolled over 24 months, assiged at random to 1500mn of metformin extended release (XR) or placebo each day followed for a mean of 3.5 years. The primary outcome will be AAA rupture or repair. The sample size of 1,954 will provide 90% pwer (p=0.05) to detect a 25% or greater reduction in the relative risk of the primary outcome. A positive finding from MAT would identify metformin as the first effective medical treatment for AAA. Since metformin is low cost, safe and available worldwide, the trial will have direct clinical implications for tens of millions of people around the world for whom no preventative therapy is currently available.
Investigators
Jon Golledge, Bruce Neal, Qiang Li, Gregory Jones, Matthew Bown, Anders Wanhainen, Richard Norman, Helen Monaghan, Dylan Morris and Joseph Moxon (College of Medicine & Dentistry, The George Institute for International Health, University of Otago, University of Leicester, University of Uppsala, Curtin University of Technology and Townsville Hospital and Health Services)
Keywords
Clinical Trial; Abdominal Aortic Aneurysm; Metformin

Tropical Australian Academic Health Centre Limited - Research Seed Grants

(COMFITE) Efficacy, acceptability and adherence with custom-made footwear in people with a history of diabetes-related foot disease.

Indicative Funding
$50,000 over 2 years
Summary
Approximately 8% (n=80,000) of Northern Australians have diabetes of whom about a quarter (n=20,000) will develop foot disease putting them at risk of amputation and death and costing ~$24 million each year. The most common cause of diabetes-related foot complications is excessive pressure on an area of an insensate foot. Footwear designed to limit pressure on the feet has been shown to reduce the risk of foot ulcers. The most appropriate type of footwear is however unknown. This pilot clinical trial examines the efficacy and acceptability of footwear designed to the shape of an individuals? feet using three-dimensional printing.
Investigators
Jon Golledge and Joseph Moxon (College of Medicine & Dentistry)
Keywords
Diabetes Foot Disease; Diabetes; Aboriginal And Torres Strait Health; Podiatry

Heart Foundation - Vanguard Grant

Metformin for treating peripheral artery disease-related walking impairment (MERIT)

Indicative Funding
$75,000 over 2 years
Summary
Blockage of the lower limb arteries (peripheral artery disease; PAD) leads to severe leg pain, walking impairment, and a substantial risk of leg amputation and death. Approximately 200 million people worldwide and approximately 1 million Australians have blocked leg arteries. This problem has recognised treatment deficiencies in comparison to other common diseases, including the absence of effective medications to increase blood supply to the legs, reduce leg pain, improve walking ability and reduce the risk of major amputation. Multiple lines of evidence suggest that metformin, a cheap and safe medication, promotes formation of new vessels, improves microcirculation and muscle function, and limits pain. In preliminary studies, metformin significantly increased blood supply to the limb of a pre-clinical model of blocked leg arteries. We have also associated metformin prescription with a 4-fold reduction in the rate of major lower limb amputation in patients with blocked arteries. This placebo-controlled, randomised clinical trial will examine the efficacy of metformin in improving walking ability in patients with blocked leg arteries over 6 months. Positive findings from this trial will identify a new treatment for a problem that affects 10-20% of adults aged over 50 years.
Investigators
Jon Golledge, Dylan Morris and Joseph Moxon (College of Medicine & Dentistry and University of Oxford)
Keywords
peripheral artery disease; Clinical Trial; Medication

QLD Department of Environment and Science - Advance Queensland Research Fellowship

Clinical and economic evaluation of novel blood tests for stroke

Indicative Funding
$300,000 over 4 years
Summary
This clinical study aims to test the ability for 2 novel blood borne markers to 1) diagnose stroke and 2) predict patient outcomes 90 days after stroke onset. In partnership with the Townsville Hospital, I will recruit presenting patients suffering suspected stroke and collect blood samples at presentation and after 24 hours as part of their usual care. Blood will be analysed for circulating concentrations of the novel markers which will be statistically compared to current gold standards in stroke assessment. Patients will be followed up at 3 months to assess disability, and perform economic analyses to quantify healthcare costs.
Investigators
Joseph Moxon (College of Medicine & Dentistry)
Keywords
Stroke; Diagnosis; Economic Analysis; Blood tests; Prognosis

Townsville Hospital and Health Service - Study Education Research Trust Account (SERTA)

Peak Wall Stress as a prognostic indicator of abdominal Aortic Aneurysm rupture risk

Indicative Funding
$50,000 over 3 years
Summary
Abdominal Aortic Aneurysm (AAA) affects 20 million people worldwide and 100,000 people in Australia. Annually, AAA rupture leads to 200,000 deaths worldwide and 2000 deaths in Australia. In clinical practice, maximum AAA diameter is the preferred surrogate measure for disease progression and rupture risk, and is used to guide surgical intervention. Approximately 10% of AAAs will rupture before they reach the current threshold for repair, whereas 60% of large AAAs remain stable during their lifetime, suggesting that diameter alone is an imperfect tool to decide which AAAs require surgical intervention. The specific aims of the project are Aim 1: To investigate if PWS is greater in patients with ruptured compared to intact AAAs matched for diameter; Aim 2: To evaluate the impact of a common anti-hypertensive medication {Telmisartan) on PWS and rupture risk in patients with small AAAs.
Investigators
Tejas Singh, Jon Golledge and Joseph Moxon in collaboration with Thomas Gasser (College of Medicine & Dentistry and Royal Institute of Technology)
Keywords
Metformin; Abdominal Aortic Aneurysm; Ruptures

Townsville Hospital and Health Service - Study Education Research Trust Account (SERTA)

Assessment of the efficacy of a novel treatment for Peripheral Artery Disease (PAD)

Indicative Funding
$50,000 over 3 years
Summary
Blockage of leg arteries (peripheral artery disease - PAD) leads to severe exertional leg pain (intermittent claudication), impaired walking ability, reduced health-related quality of life, and high risk of amputation and death. Multiple lines of evidence suggest that metformin, a cheap and safe medication, promotes formation of new vessels, improves microcirculation and muscle function,s and limits pain.
Investigators
Jon Golledge, Joseph Moxon, Tejas Singh, Rachel Wong, Kunwargit Sangla and Veronica White (College of Medicine & Dentistry and Townsville Hospital and Health Services)
Keywords
Metformin; peripheral artery disease; Intermittent Claudication

Royal Australasian College of Surgeons RACS - James Ramsay Project Grant

Metformin in the management of abdominal aortic aneurysm (MAGIC)

Indicative Funding
$156,000 over 2 years
Summary
MAGIC will be the first trial to assess the value of metformin wiuth significant preliminary data to suggest it can slow AAA growth. This trial offers the possibility of identifying a new treatment modality for an increasingly common condition, which would markedly change clinical practice.
Investigators
Jon Golledge, Dylan Morris, Paul Norman, Joseph Moxon, Zanfina Ademi, Rachel Neale, Anders Wanhainen, Ronald Dalman, Robert Hinchliffe and Matthew Bown in collaboration with Anthony Dear, Bernard Bourke, Christopher Reid, Jason Jenkins, Derek Chew, Rachael Jones, Richard Norman and Stephen Colagiuri (College of Medicine & Dentistry, University of Oxford, The University of Western Australia, Monash University, QIMR Berghofer, University of Uppsala, Stanford University, University of Bristol, University of Leicester, Gosford Hospital, The University of Queensland, Flinders University, Curtin University of Technology and University of Sydney)
Keywords
Aortic Aneurysm; Clinical Trials; Surgery

Diabetes Australia - General Grant

Testing a novel treatment for diabetes-associated ischemic foot ulceration.

Indicative Funding
$60,000 over 1 year
Summary
5000 Australians with diabetes have a leg amputations each year. This project investigates a novel drug therapy approach to reducing the need for leg amputations within an established rodent model. The aim of the study is to assess if administration of a direct activator of adenosine-5'-monophosphate (AMP)-activated protein kinase (AMPK) will promote healing within a rat model of diabetes and limb ischaemia-associated foot ulceration.
Investigators
Jon Golledge, Smriti Krishna and Joseph Moxon in collaboration with Jon Oakhill, Michelle Keske and Valerie Schini-Kerth (College of Medicine & Dentistry, St Vincent's Institute of Medical Research, Deakin University and University of Strasbourg)
Keywords
peripheral artery disease; Diabetes; rodent model
Supervision

Advisory Accreditation: I can be on your Advisory Panel as a Primary or Secondary Advisor.

These Higher Degree Research projects are either current or by students who have completed their studies within the past 5 years at JCU. Linked titles show theses available within ResearchOnline@JCU.

Current
  • Diabetic foot disease and prevention of its complications (PhD , Secondary Advisor)
  • Assessment and Intervention of Dietary Patterns in Patients with Peripheral Arterial Disease and Abdominal Aortic Aneurysm (PhD , Secondary Advisor)
Completed
Data

These are the most recent metadata records associated with this researcher. To see a detailed description of all dataset records, visit Research Data Australia.

Collaboration

The map shows research collaborations by institution from the past 7 years.
Note: Map points are indicative of the countries or states that institutions are associated with.

  • 5+ collaborations
  • 4 collaborations
  • 3 collaborations
  • 2 collaborations
  • 1 collaboration
  • Indicates the Tropics (Torrid Zone)

Connect with me
Share my profile
Share my profile:
jcu.me/joseph.moxon

Email
Phone
Location
  • 48.212, AITHM (Townsville campus)
Advisory Accreditation
Primary Advisor
Find me on…
Icon for Google Scholar profile Icon for Scopus Author page Icon for ORCID profile Icon for ResearchGate profile

Similar to me

  1. Dr Corey Moran
    College of Medicine & Dentistry
  2. Dr Shiv Thanigaimani
    College of Medicine & Dentistry
  3. Dr Tejas Singh
    College of Medicine & Dentistry
  4. Dr Smriti Murali Krishna
    College of Medicine & Dentistry
  5. Prof Jon Golledge
    College of Medicine & Dentistry